2017 ASCO Annual Meeting

Solid Tumors
Breast Cancer

Adjuvant Pertuzumab in HER2-Positive Breast Cancer: Value Yet to Be Demonstrated

The ASCO Post issue of June 25, 2017, did an excellent job of summarizing the results and controversy generated by the initial results of the APHINITY trial, reported at the 2017 ASCO Annual Meeting a...

World Oncology Leaders Reunion


Colorectal Cancer

New Data Reported on Vemurafenib, Vitamin D, Selective Internal Radiotherapy, and Circulating Tumor DNA in Colorectal Cancer

RESULTS OF the IDEA trial, which showed that some patients with stage III low-risk colon cancer may require less oxaliplatin therapy (see the June 25 issue of The ASCO Post), were among the findings h...

Colorectal Cancer

Expert Point of View: Frank Sinicrope, MD

FRANK SINICROPE, MD, Professor of Oncology and Co-Leader of the GI Cancer Program at the Mayo Clinic, Rochester, said CHARTA addressed whether patient outcomes can be improved with a triplet regimen ...

Colorectal Cancer

More Support for FOLFOXIRI/Bevacizumab in Advanced Colorectal Cancer

A RANDOMIZED head-to-head comparison in patients with advanced colorectal cancer found that a regimen of FOLFOXIRI (fluorouracil/leucovorin, oxaliplatin, irinotecan) plus bevacizumab (Avastin) was mo...

CNS Cancers

In Case You Missed It: Short Takes on Current Cancer Research

MOST ONCOLOGISTS are familiar with the findings of the plenary sessions featured at the 2017 ASCO Annual Meeting, with topics ranging from the duration of adjuvant oxaliplatin-based therapy in stage I...

Supportive Care

Are Wearable Physical Activity Monitors Coming of Age in Oncology?

COMMERCIALLY AVAILABLE wearable physical activity monitors have been making their way into clinical research in recent years; however, most studies on these devices have been related to non-cancer co...

Lung Cancer

Expert Point of View: Anne Tsao, MD, and John Heymach, MD, PhD

STUDY DISCUSSANT Anne Tsao, MD, Director of the Mesothelioma Program at The University of Texas MD Anderson Cancer Center in Houston, indicated the response rates seen in the MAPS-2 trial are compara...

Lung Cancer

Checkpoint Inhibitors May Prove to Be Effective in Mesothelioma

CHECKPOINT INHIBITION was effective against malignant pleural mesothelioma in the MAPS-2 study of the French Cooperative Thoracic Intergroup. At the 2017 ASCO Annual Meeting, researchers reported a d...

Gynecologic Cancers

Expert Point of View: Ritu Salani, MD, MBA

STUDY DISCUSSANT Ritu Salani, MD, MBA, of The Ohio State University Wexner Medical Center, Columbus, agreed with the LION trial investigators.  “Omitting systemic lymph node dissection in patients wh...

Gynecologic Cancers

Study Supports Omission of Lymphadenectomy in Node-Negative Advanced Ovarian Cancer

SYSTEMATIC LYMPHADENECTOMY in patients with advanced ovarian cancer and complete resection offered no improvement in progression-free or overall survival in the Gynecologic Cancer Intergroup’s LION t...

Solid Tumors

Expert Point of View: Siwen Hu-Lieskovan, MD

“COMBINATION STRATEGIES are being developed, but the big question is what and how to combine,” said formal discussant Siwen Hu-Lieskovan, MD, of the University of California Los Angeles. “Anti–progra...

Solid Tumors

Combination Strategies for Jump-Starting the Immune Response

CHECKPOINT INHIBITORS have dramatically changed the landscape of the treatment of melanoma, lung, bladder, and other cancers. Researchers are focusing on exploring ways to extend the use of checkpoint...

Colorectal Cancer

Expert Point of View: Steven J. Cohen, MD, and Josep Tabarnero, MD, PhD

STEVEN J. COHEN, MD, Director of the Rosenfeld Cancer Center at Jefferson Health/Abington Hospital, Abington, Pennsylvania, and Vice Chair of Medical Oncology at Sidney Kimmel Cancer Center at Jeffe...

Colorectal Cancer

Tumor ‘Sidedness’ in Colon Cancer: Studies Look for Explanations

TUMOR “SIDEDNESS” in colon cancer has become a topic of great interest, after right-sided tumors were shown to have a worse prognosis than left-sided ones and biologics were found to differ in effica...

Symptom Management

Expert Point of View: Joshua Jones, MD

ASCO EXPERT Joshua Jones, MD, Assistant Professor of Radiation Oncology at the Hospital of the University of Pennsylvania, Philadelphia, commented on the study at a press briefing.  “This is a case w...

Skin Cancer
CNS Cancers

Drug Combinations Prove Effective Against Melanoma Brain Metastases

STUDIES PRESENTED at the 2017 ASCO Annual Meeting have shown that for melanoma that metastasizes to the brain, the combined use of checkpoint inhibitors and targeted agents can be effective.  In COMBI...

Breast Cancer

Expert Point of View: Leisha A. Emens, MD, PhD

STUDY DISCUSSANT Leisha A. Emens, MD, PhD, of Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins University, Baltimore, entitled her remarks, “Target Practice in Triple-Negative Bre...

Breast Cancer

Potent PARP Inhibitor Moves Ahead in BRCA-Mutated Breast Cancer

TALAZOPARIB, a novel inhibitor of poly (ADP-ribose) polymerase (PARP), showed encouraging efficacy in breast cancer patients with BRCA1/2 mutations in the phase II ABRAZO trial, presented at the 2017...

Lung Cancer

Retreatment With Checkpoint Inhibitors May Be Feasible for Some Patients With NSCLC

INCREASING NUMBERS of patients are being treated with checkpoint inhibitors, and about one-quarter to one-third will develop immune-related adverse events. One question on the minds of oncologists is...

Lung Cancer

Expert Point of View: John Heymach, MD

"TO PUT THESE RESULTS into context, currently we have three approved epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for EGFR-positive non–small cell lung cancer (NSCLC): gefitinib...

Lung Cancer

Dacomitinib Outperforms Gefitinib in EGFR-Positive NSCLC

DACOMITINIB, a second-generation epidermal growth factor receptor (EGFR)-targeted tyrosine kinase inhibitor, outperformed gefitinib (Iressa) as first-line treatment for EGFR-positive advanced non–sma...

Kidney Cancer

Expert Point of View: Hans Hammers, MD, PhD

THE COMBINATION of checkpoint inhibitors and vascular endothelial growth factor (VEGF) inhibitors is attractive in renal cell carcinoma, said formal discussant of this trial, Hans Hammers, MD, PhD, o...

Kidney Cancer

Atezolizumab/Bevacizumab Moves Forward in Metastatic Renal Cell Carcinoma

THE COMBINATION of atezolizumab (Tecentriq) plus bevacizumab (Avastin) showed promising results as first-line treatment of patients with metastatic renal cell carcinoma, according to a phase II trial...


Expert Point of View: Nitin Jain, MD, and Susan O'Brien, MD

Formal discussant of the GENUINE trial, Nitin Jain, MD, of The University of Texas MD Anderson Cancer Center, Houston, noted that the majority of responses to ibrutinib (Imbruvica) in high-risk patie...


Ublituximab/Ibrutinib Beneficial in Patients With Chronic Lymphocytic Leukemia

The addition of ublituximab (a glycoengineered anti-CD20 antibody) to ibrutinib (Imbruvica) improved response rates, depth of response, and led to quicker resolution of ibrutinib-associated lymphocyt...

Multiple Myeloma

Expert Point of View: Michael S. Sabel, MD; Marcela Maus, MD, PhD; and Carl June, MD

"We are now seeing the merger of immunotherapy with precision medicine. This is the epitome of personalized medicine,” said ASCO-invited expert Michael S. Sabel, MD, Chief of the Division of Surgica...

Multiple Myeloma

CAR T-Cell Therapy in Multiple Myeloma Yields 100% Response Rate

Chinese investigators reported that 100% of patients with relapsed or refractory multiple myeloma responded to autologous chimeric antigen receptor (CAR) T-cell therapy, and 14 of 19 (74%) who were ...

Breast Cancer

Expert Point of View: Leisha A. Emens, MD, PhD

Leisha A. Emens, MD, PhD, of the Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins University, commented on the promise of anti–programmed cell death protein 1/programmed cell deat...

Breast Cancer

Pembrolizumab Moving Forward in Triple-Negative Breast Cancer

In the treatment of triple-negative breast cancer, checkpoint inhibition is making inroads in both early- and late-stage disease, and the line of treatment and expression of the programmed cell death...

Breast Cancer

Positive Results for APHINITY, but Value of Benefit of Dual HER2 Blockade Questioned

The results of the long-awaited APHINITY trial are in, and although the phase III study met its primary endpoint, it failed to establish dual HER2 blockade as the optimal adjuvant treatment for early ...

Breast Cancer

Pregnancy After Breast Cancer

Findings from a retrospective study showed that women who became pregnant after an early breast cancer diagnosis, including those with estrogen receptor–positive tumors, did not have a higher chance o...

Lung Cancer

Alectinib vs Crizotinib in First-Line Treatment of ALK-Positive NSCLC

In 2011, crizotinib (Xalkori) became the first effective targeted therapy for anaplastic lymphoma kinase (ALK)-positive non–small cell lung cancer (NSCLC). Now data from a phase III trial show that al...

Health-Care Policy

SWOG Clinical Trials Have Yielded Positive Return on Investment

The National Cancer Institute (NCI)-funded SWOG clinical trials program has added 3.34 million years of life for patients with cancer in the United States because of successful therapies that were va...

Solid Tumors

Novel Tropomyosin Receptor Kinase Inhibitor Yields High Response Rates Across Tumor Types

Larotrectinib, an oral inhibitor of tropomyosin receptor kinase, showed “striking” activity in adult and pediatric patients with the genetic aberrations known as tropomyosin receptor kinase (TRK) fusi...

Breast Cancer

Abemaciclib Plus Fulvestrant Delays Breast Cancer Progression in MONARCH 2

In the treatment of metastatic estrogen receptor–positive breast cancer, a highly significant 45% reduction in progression was achieved with abemaciclib, combined with fulvestrant (Faslodex), in the g...

Breast Cancer

Olaparib Improves Progression-Free Survival in BRCA-Associated Breast Cancer

The PARP INHIBITOR olaparib (Lynparza) improved progression-free survival in women with HER2-negative metastatic breast cancer that was either hormone receptor–positive or triple-negative in patients ...

Prostate Cancer

Two Studies Show Abiraterone Plus Prednisolone/Prednisone Added to Standard Hormone Therapy Improves Survival in Advanced Prostate Cancer

The addition of abiraterone acetate (Zytiga) plus prednisolone/prednisone to standard androgen-deprivation therapy improves survival in men starting treatment for locally advanced or metastatic, hormo...

Symptom Management

Online Self-Reporting of Symptoms Improves Quality of Life, Extends Survival

When patients with metastatic cancer used a Web-based tool to self-report symptoms proactively during treatment, they lived 5 months longer than did patients assigned to usual care. In addition, they ...

Gastrointestinal Cancer

Some Patients With Stage III Low-Risk Colon Cancer May Require Less Oxaliplatin Therapy

Patients with stage III colon cancer considered at low risk for recurrence may be treated effectively—and incur less neurotoxicity—with 3 months of an oxaliplatin-based regimen as compared with the st...

Supportive Care

Expert Point of View: Richard L. Schilsky, MD, and Don Dizon, MD

“[THE STREAM, Conquer Fear, and CALM] studies focus on the psychosocial aspects of coping with cancer. One theme that binds them is that oncologists take pride in the fact that we treat people with ...

Supportive Care

Brief Psychological Interventions Positively Affect Cancer Patients’ Well-Being

Three separate brief psychological interventions aimed at helping cancer patients cope with distress have shown improvements in quality of life and well-being across the continuum of cancer care. The ...

health-care policy

ASCO 2017: SWOG Clinical Trials Have Added More Than 3 Million Years of Life for Patients With Cancer

For an investment of $125 for each year of life gained since the 1950s, the National Cancer Institute (NCI)-funded SWOG clinical trials program has added 3.34 million years of life for patients with c...

neuroendocrine tumors

Greta Stifel on Neuroendocrine Tumors: A Patient's Message to Physicians 

Greta Stifel recounts her story about a misdiagnosed tumor and urges physicians to raise awareness of neuroendocrine disease.

lung cancer
colorectal cancer

David H. Henry, MD, on Advances in Lung Cancer, Colorectal Cancer: Expert Perspective

David H. Henry, MD, of Pennsylvania Oncology Hematology Associates, outlines abstracts focusing on chemotherapy in locally advanced rectal cancer and immune-related toxicity, response to anti–PD-L1 bl...

breast cancer

Lisa A. Carey, MD, and Richard S. Finn, MD, on Breast Cancer: Findings From the PALOMA-1/TRIO 18 Trial

Lisa A. Carey, MD, of the University of North Carolina, and Richard S. Finn, MD, of UCLA Medical Center, discuss phase II overall survival findings on palbociclib in combination with letrozole vs letr...

lung cancer

Arnaud Scherpereel, MD, PhD, on Mesothelioma: Results From the IFCT-1501 MAPS2 Trial (French Language Version)

Arnaud Scherpereel, MD, PhD, of the University Hospital of Lille, discusses in French phase II study findings on second- or third-line nivolumab vs nivolumab plus ipilimumab in malignant pleural mesot...

lung cancer

Arnaud Scherpereel, MD, PhD, on Mesothelioma: Results From the IFCT-1501 MAPS2 Trial

Arnaud Scherpereel, MD, PhD, of the University Hospital of Lille, discusses phase II study findings on second- or third-line nivolumab vs nivolumab plus ipilimumab in malignant pleural mesothelioma pa...

global cancer care

Rakesh Chopra, MD, on Global Health Care: Expert Perspective

Rakesh Chopra, MD, of India’s Artemis Hospitals, discusses ASCO’s Role in global cancer care and the issues he finds most pressing.

bladder cancer

Elizabeth R. Plimack, MD, on Advanced Urothelial Cancer: Expert Perspective

Elizabeth R. Plimack, MD, of Fox Chase Cancer Center, discusses highlights of three important abstracts on advanced and metastatic urothelial cancer presented at the 2017 ASCO Annual Meeting. (Abstrac...




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.